Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trialsFanyue Meng, Fengcai Zhu, Fan Gao et al.|Signal Transduction and Targeted Therapy|2021Cited by 36
New insights from network analysis on the biogeography of antiarchs (jawed stem-Gnathostomata)Zhaohui Pan, Min Zhu, Fanyue Meng et al.|Palaeoworld|2022Cited by 4